View ValuationKDventures 将来の成長Future 基準チェック /06現在、 KDventuresの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長37.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報Price Target Changed • Nov 18Price target decreased by 13% to kr1.75Down from kr2.00, the current price target is provided by 1 analyst. New target price is 117% above last closing price of kr0.81. Stock is down 30% over the past year. The company posted a net loss per share of kr0.03 last year.Price Target Changed • May 19Price target decreased by 7.7% to kr2.10Down from kr2.28, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.00. Stock is down 38% over the past year. The company posted a net loss per share of kr0.03 last year.Price Target Changed • Nov 16Price target decreased to kr5.40Down from kr6.10, the current price target is provided by 1 analyst. New target price is 160% above last closing price of kr2.08. Stock is down 73% over the past year. The company posted earnings per share of kr0.97 last year.Price Target Changed • Apr 27Price target increased to kr7.90Up from kr6.10, the current price target is provided by 1 analyst. New target price is 158% above last closing price of kr3.06. Stock is up 98% over the past year. The company posted earnings per share of kr0.97 last year.すべての更新を表示Recent updatesお知らせ • Jun 23+ 2 more updatesKDventures AB to Report Q4, 2026 Results on Feb 11, 2027KDventures AB announced that they will report Q4, 2026 results on Feb 11, 2027Reported Earnings • May 05First quarter 2026 earnings released: kr0.068 loss per share (vs kr0.053 loss in 1Q 2025)First quarter 2026 results: kr0.068 loss per share (further deteriorated from kr0.053 loss in 1Q 2025). Net loss: kr34.1m (loss widened 141% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 32 percentage points per year, which is a significant difference in performance.お知らせ • Apr 07KDventures AB, Annual General Meeting, May 12, 2026KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna SwedenReported Earnings • Mar 25Full year 2025 earnings released: kr0.72 loss per share (vs kr0.03 loss in FY 2024)Full year 2025 results: kr0.72 loss per share (further deteriorated from kr0.03 loss in FY 2024). Net loss: kr193.9m (loss widened kr185.8m from FY 2024). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 49% per year.お知らせ • Mar 03KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian SyndromeKDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026.Reported Earnings • Feb 16Full year 2025 earnings released: kr0.72 loss per share (vs kr0.03 loss in FY 2024)Full year 2025 results: kr0.72 loss per share (further deteriorated from kr0.03 loss in FY 2024). Net loss: kr193.9m (loss widened kr185.8m from FY 2024). Over the last 3 years on average, earnings per share has fallen by 46% per year and the company’s share price has also fallen by 46% per year.New Risk • Jan 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 142% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (142% increase in shares outstanding). Revenue is less than US$1m (kr1.7m revenue, or US$197k). Minor Risk Market cap is less than US$100m (kr185.7m market cap, or US$21.0m).お知らせ • Jan 29Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 384,166,664 Price\Range: SEK 0.3 Transaction Features: Rights OfferingNew Risk • Jan 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr88.6m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (kr1.7m revenue, or US$189k). Market cap is less than US$10m (kr88.6m market cap, or US$9.62m).New Risk • Dec 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr92.8m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (kr1.7m revenue, or US$185k). Market cap is less than US$10m (kr92.8m market cap, or US$9.87m).New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (kr1.7m revenue, or US$184k). Minor Risk Market cap is less than US$100m (kr118.6m market cap, or US$12.6m).お知らせ • Dec 01Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 675,193,985 Price\Range: SEK 0.3 Transaction Features: Rights OfferingPrice Target Changed • Nov 18Price target decreased by 13% to kr1.75Down from kr2.00, the current price target is provided by 1 analyst. New target price is 117% above last closing price of kr0.81. Stock is down 30% over the past year. The company posted a net loss per share of kr0.03 last year.Reported Earnings • Nov 15Third quarter 2025 earnings released: kr0.25 loss per share (vs kr0.04 loss in 3Q 2024)Third quarter 2025 results: kr0.25 loss per share (further deteriorated from kr0.04 loss in 3Q 2024). Net loss: kr66.8m (loss widened kr55.9m from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.お知らせ • Nov 05Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemiaKarolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated.お知らせ • Sep 04Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Security Name: Shares Security Type: Common Stock Transaction Features: Rights OfferingReported Earnings • Aug 31Second quarter 2025 earnings released: kr0.27 loss per share (vs kr0.059 loss in 2Q 2024)Second quarter 2025 results: kr0.27 loss per share (further deteriorated from kr0.059 loss in 2Q 2024). Net loss: kr73.3m (loss widened 359% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.お知らせ • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026お知らせ • Jun 30An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.Price Target Changed • May 19Price target decreased by 7.7% to kr2.10Down from kr2.28, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.00. Stock is down 38% over the past year. The company posted a net loss per share of kr0.03 last year.分析記事 • May 09We Discuss Why Karolinska Development AB (publ)'s (STO:KDEV) CEO Compensation May Be Closely ReviewedKey Insights Karolinska Development to hold its Annual General Meeting on 15th of May CEO Viktor Drvota's total...Reported Earnings • May 02First quarter 2025 earnings released: kr0.053 loss per share (vs kr0.001 profit in 1Q 2024)First quarter 2025 results: kr0.053 loss per share (down from kr0.001 profit in 1Q 2024). Net loss: kr14.2m (down kr14.4m from profit in 1Q 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.お知らせ • Apr 08Karolinska Development AB (publ), Annual General Meeting, May 15, 2025Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, SwedenReported Earnings • Mar 24Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: kr0.03 loss per share (down from kr0.02 profit in FY 2023). Net loss: kr8.10m (down 250% from profit in FY 2023). Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 67%. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Reported Earnings • Feb 17Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: kr0.03 loss per share (down from kr0.02 profit in FY 2023). Net loss: kr8.10m (down 250% from profit in FY 2023). Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 67%. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings.New Risk • Feb 15New major risk - Revenue and earnings growthEarnings have declined by 37% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m (kr1.9m revenue, or US$176k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr24m net loss in 2 years). Market cap is less than US$100m (kr280.6m market cap, or US$26.2m).お知らせ • Dec 19Karolinska Development AB Announces Changes to ChairmanKarolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics.お知らせ • Dec 11Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the BoardKarolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.お知らせ • Nov 15Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF VaccinesKarolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B.お知らせ • Sep 23An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.New Risk • Sep 01New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr1.9m revenue, or US$185k). Minor Risk Market cap is less than US$100m (kr357.3m market cap, or US$34.8m).Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 40% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.お知らせ • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025分析記事 • May 04We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising EarningsKarolinska Development AB (publ)'s ( STO:KDEV ) robust recent earnings didn't do much to move the stock. We think this...Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has remained flat, which means it is well ahead of earnings.お知らせ • Apr 16Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-ElectionKarolinska Development AB (publ) announced that Björn Cochlovius has declined re-election.Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 23% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has remained flat, which means it is well ahead of earnings.New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (kr428.5m market cap, or US$40.5m).Recent Insider Transactions • Feb 22Chief Executive Officer recently bought kr81k worth of stockOn the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly kr1.62 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months.Reported Earnings • Feb 18Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.お知らせ • Feb 03+ 5 more updatesKarolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024Karolinska Development AB (publ) announced that they will report first half, 2024 results on Aug 30, 2024Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.044 (up from kr0.17 loss in 3Q 2022). Net income: kr12.0m (up kr58.6m from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 12% per year.お知らせ • Nov 09Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,150,000 Price\Range: SEK 2 Transaction Features: Rights Offeringお知らせ • Sep 21Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal SurgeryKarolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models.Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 28%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Jun 22Chief Legal Officer & Deputy CEO recently bought kr165k worth of stockOn the 20th of June, Johan Dighed bought around 100k shares on-market at roughly kr1.65 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr466k more in shares than they have sold in the last 12 months.Recent Insider Transactions • May 08Chief Legal Officer & Deputy CEO recently bought kr56k worth of stockOn the 4th of May, Johan Dighed bought around 35k shares on-market at roughly kr1.61 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr89k. Insiders have collectively bought kr301k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Mar 29Chief Legal Officer & Deputy CEO recently bought kr89k worth of stockOn the 27th of March, Johan Dighed bought around 50k shares on-market at roughly kr1.78 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr245k more in shares than they have sold in the last 12 months.Reported Earnings • Mar 28Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 28%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.Reported Earnings • Feb 19Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 28%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.お知らせ • Feb 15Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive DataKarolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.Recent Insider Transactions • Dec 23Chief Legal Officer & Deputy CEO recently bought kr84k worth of stockOn the 19th of December, Johan Dighed bought around 50k shares on-market at roughly kr1.67 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr156k more in shares than they have sold in the last 12 months.Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 33%.お知らせ • Nov 19+ 1 more updateKarolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023Karolinska Development AB (publ) announced that they will report first half, 2023 results on Aug 25, 2023お知らせ • Nov 18Karolinska Development AB (publ), Annual General Meeting, May 16, 2023Karolinska Development AB (publ), Annual General Meeting, May 16, 2023.Price Target Changed • Nov 16Price target decreased to kr5.40Down from kr6.10, the current price target is provided by 1 analyst. New target price is 160% above last closing price of kr2.08. Stock is down 73% over the past year. The company posted earnings per share of kr0.97 last year.Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 91% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Aug 19+ 2 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Karolinska Development AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improved over the past weekAfter last week's 20% share price gain to kr3.04, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 10% over the past three years.Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 103% growth forecast for the industry in Sweden.Price Target Changed • Apr 27Price target increased to kr7.90Up from kr6.10, the current price target is provided by 1 analyst. New target price is 158% above last closing price of kr3.06. Stock is up 98% over the past year. The company posted earnings per share of kr0.97 last year.Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.Reported Earnings • Mar 29Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)Full year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Over the next year, revenue is expected to shrink by 7.8% compared to a 112% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to kr2.86, the stock trades at a trailing P/E ratio of 4.5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 47% over the past three years.Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 73% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.Valuation Update With 7 Day Price Move • Jan 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr5.08, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 19x in the Pharmaceuticals industry in Sweden. Total loss to shareholders of 15% over the past three years.Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr5.05, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 20x in the Pharmaceuticals industry in Sweden. Total loss to shareholders of 21% over the past three years.Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has remained flat, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improved over the past weekAfter last week's 22% share price gain to kr4.68, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.Valuation Update With 7 Day Price Move • Oct 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr4.22, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 42% over the past three years.Valuation Update With 7 Day Price Move • Sep 10Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to kr4.05, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 113x in the Pharmaceuticals industry in Sweden. Total loss to shareholders of 53% over the past three years.Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.分析記事 • Aug 19Is Karolinska Development (STO:KDEV) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • May 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.分析記事 • Apr 27Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This YearKarolinska Development AB (publ) ( STO:KDEV ) has not performed well recently and CEO Viktor Drvota will probably need...Reported Earnings • Mar 30Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.Executive Departure • Mar 10CFO & Deputy CEO Fredrik Jarrsten has left the companyOn the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (kr216k worth at the time). A total of 5 executives have left over the last 12 months.Is New 90 Day High Low • Feb 25New 90-day low: kr1.59The company is down 31% from its price of kr2.31 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period.Reported Earnings • Feb 13Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、KDventures は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OM:KDV B - アナリストの将来予測と過去の財務データ ( )SEK Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20262-214-24-24N/A12/31/20252-194-26-26N/A9/30/20252-136-27-27N/A6/30/20252-80-34-34N/A3/31/20252-23-28-28N/A12/31/20242-8-28-28N/A9/30/20242-29-26-26N/A6/30/20242-6-24-24N/A3/31/2024234-22-22N/A12/31/202325-25-25N/A9/30/2023217-26-26N/A6/30/20232-41-27-27N/A3/31/20232-87-27-27N/A12/31/20222-88-33-33N/A9/30/20222-118-31-31N/A6/30/20222-721010N/A3/31/202221661010N/A12/31/202121711717N/A9/30/202122764747N/A6/30/2021210822N/A3/31/20212-106-6-6N/A12/31/20203-207-33-33N/A9/30/2020335-19-19N/A6/30/20203190-41-41N/A3/31/20204195-36-36N/A12/31/20193303N/A-7N/A9/30/20194-11N/A-6N/A6/30/201948N/A18N/A3/31/2019332N/A19N/A12/31/2018331N/A13N/A9/30/2018348N/A-60N/A6/30/20183238N/A-56N/A3/31/20183185N/A-49N/A12/31/20172180N/A-31N/A9/30/20175125N/A-6N/A6/30/20175-87N/A3N/A3/31/20175-142N/A6N/A12/31/20165-217N/A-9N/A9/30/20162-315N/A-32N/A6/30/20162-325N/A-95N/A3/31/20163-904N/A-122N/A12/31/20153-1,055N/A-325N/A9/30/20154-980N/A-375N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: KDV Bの予測収益成長が 貯蓄率 ( 2% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: KDV Bの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: KDV Bの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: KDV Bの収益がSwedish市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: KDV Bの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: KDV Bの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/01 21:24終値2026/07/01 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋KDventures AB 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。4 アナリスト機関Johan LöchenABG Sundal Collier SponsoredEspen JørgensenDNB CarnegieKlas PalinDNB Carnegie Commissioned Research1 その他のアナリストを表示
Price Target Changed • Nov 18Price target decreased by 13% to kr1.75Down from kr2.00, the current price target is provided by 1 analyst. New target price is 117% above last closing price of kr0.81. Stock is down 30% over the past year. The company posted a net loss per share of kr0.03 last year.
Price Target Changed • May 19Price target decreased by 7.7% to kr2.10Down from kr2.28, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.00. Stock is down 38% over the past year. The company posted a net loss per share of kr0.03 last year.
Price Target Changed • Nov 16Price target decreased to kr5.40Down from kr6.10, the current price target is provided by 1 analyst. New target price is 160% above last closing price of kr2.08. Stock is down 73% over the past year. The company posted earnings per share of kr0.97 last year.
Price Target Changed • Apr 27Price target increased to kr7.90Up from kr6.10, the current price target is provided by 1 analyst. New target price is 158% above last closing price of kr3.06. Stock is up 98% over the past year. The company posted earnings per share of kr0.97 last year.
お知らせ • Jun 23+ 2 more updatesKDventures AB to Report Q4, 2026 Results on Feb 11, 2027KDventures AB announced that they will report Q4, 2026 results on Feb 11, 2027
Reported Earnings • May 05First quarter 2026 earnings released: kr0.068 loss per share (vs kr0.053 loss in 1Q 2025)First quarter 2026 results: kr0.068 loss per share (further deteriorated from kr0.053 loss in 1Q 2025). Net loss: kr34.1m (loss widened 141% from 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 32 percentage points per year, which is a significant difference in performance.
お知らせ • Apr 07KDventures AB, Annual General Meeting, May 12, 2026KDventures AB, Annual General Meeting, May 12, 2026, at 15:00 W. Europe Standard Time. Location: nanna svartz vag 2, 171 65 solna, solna Sweden
Reported Earnings • Mar 25Full year 2025 earnings released: kr0.72 loss per share (vs kr0.03 loss in FY 2024)Full year 2025 results: kr0.72 loss per share (further deteriorated from kr0.03 loss in FY 2024). Net loss: kr193.9m (loss widened kr185.8m from FY 2024). Over the last 3 years on average, earnings per share has fallen by 46% per year whereas the company’s share price has fallen by 49% per year.
お知らせ • Mar 03KDventures AB Announces Organon Discontinues Development of Forendo's Drug Candidate for Polycystic Ovarian SyndromeKDventures AB announced that Organon has discontinued the development of a preclinical drug candidate for polycystic ovarian syndrome (PCOS) that was part of the acquisition of the portfolio company Forendo. Thus, the development of both drug candidates included in the acquisition has been discontinued. KDventures will therefore write off its entire remaining book value of the agreement on potential additional purchase considerations entered into between the parties in connection with the acquisition. In 2021, Organon acquired KDventures' portfolio company Forendo, but in July 2025 discontinued development of OG-6219, its most advanced drug candidate targeting endometriosis. The acquisition also included a preclinical drug candidate for polycystic ovary syndrome. Organon has now announced that development of this drug candidate has also been discontinued. This announcement means that the value of KDventures' share of the parties’ agreement on potential additional purchase considerations will be written off in its entirety, which will be reported in the interim report for the first quarter of 2026.
Reported Earnings • Feb 16Full year 2025 earnings released: kr0.72 loss per share (vs kr0.03 loss in FY 2024)Full year 2025 results: kr0.72 loss per share (further deteriorated from kr0.03 loss in FY 2024). Net loss: kr193.9m (loss widened kr185.8m from FY 2024). Over the last 3 years on average, earnings per share has fallen by 46% per year and the company’s share price has also fallen by 46% per year.
New Risk • Jan 29New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 142% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (142% increase in shares outstanding). Revenue is less than US$1m (kr1.7m revenue, or US$197k). Minor Risk Market cap is less than US$100m (kr185.7m market cap, or US$21.0m).
お知らせ • Jan 29Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 115.249999 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 384,166,664 Price\Range: SEK 0.3 Transaction Features: Rights Offering
New Risk • Jan 13New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr88.6m (US$9.62m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (kr1.7m revenue, or US$189k). Market cap is less than US$10m (kr88.6m market cap, or US$9.62m).
New Risk • Dec 04New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: kr92.8m (US$9.87m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (kr1.7m revenue, or US$185k). Market cap is less than US$10m (kr92.8m market cap, or US$9.87m).
New Risk • Dec 01New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Swedish stocks, typically moving 13% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (13% average weekly change). Earnings have declined by 20% per year over the past 5 years. Revenue is less than US$1m (kr1.7m revenue, or US$184k). Minor Risk Market cap is less than US$100m (kr118.6m market cap, or US$12.6m).
お知らせ • Dec 01Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 202.558196 million. Security Name: Class B Shares Security Type: Common Stock Securities Offered: 675,193,985 Price\Range: SEK 0.3 Transaction Features: Rights Offering
Price Target Changed • Nov 18Price target decreased by 13% to kr1.75Down from kr2.00, the current price target is provided by 1 analyst. New target price is 117% above last closing price of kr0.81. Stock is down 30% over the past year. The company posted a net loss per share of kr0.03 last year.
Reported Earnings • Nov 15Third quarter 2025 earnings released: kr0.25 loss per share (vs kr0.04 loss in 3Q 2024)Third quarter 2025 results: kr0.25 loss per share (further deteriorated from kr0.04 loss in 3Q 2024). Net loss: kr66.8m (loss widened kr55.9m from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
お知らせ • Nov 05Modus Therapeutics Receives Approval for Second Part of Phase 2 Study in Chronic Kidney Disease with anemiaKarolinska Development AB announced that its portfolio company, Modus Therapeutics, has received regulatory approval to initiate the second part of the phase 2 study with sevuparin as a treatment of chronic kidney disease with anemia. The study will be initiated in fourth quarter of 2025, in line with the company's development timeline. Modus Therapeutics, listed on Nasdaq First North Growth Market, has received approval from regulatory authorities in Italy to initiate the second part of The company's phase 2 study with sevuparin in patients with chronic kidney disease with anemic. Three doses of sevuparin will be evaluated in the second part of the clinical study, based on single-dose data from the initial part, where data shows that sevuparin was well-tolerated.
お知らせ • Sep 04Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million.Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 28.3 million. Security Name: Shares Security Type: Common Stock Transaction Features: Rights Offering
Reported Earnings • Aug 31Second quarter 2025 earnings released: kr0.27 loss per share (vs kr0.059 loss in 2Q 2024)Second quarter 2025 results: kr0.27 loss per share (further deteriorated from kr0.059 loss in 2Q 2024). Net loss: kr73.3m (loss widened 359% from 2Q 2024). Over the last 3 years on average, earnings per share has increased by 55% per year but the company’s share price has fallen by 28% per year, which means it is significantly lagging earnings.
お知らせ • Jul 09+ 4 more updatesKarolinska Development AB (publ) to Report Nine Months, 2026 Results on Nov 13, 2026Karolinska Development AB (publ) announced that they will report nine months, 2026 results on Nov 13, 2026
お知らせ • Jun 30An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025. An undisclosed buyer completed the acquisition of an unknown minority stake in OssDsign AB (publ) (OM:OSSD) from Karolinska Development AB (publ) (OM:KDEV) on June 30, 2025.
Price Target Changed • May 19Price target decreased by 7.7% to kr2.10Down from kr2.28, the current price target is provided by 1 analyst. New target price is 110% above last closing price of kr1.00. Stock is down 38% over the past year. The company posted a net loss per share of kr0.03 last year.
分析記事 • May 09We Discuss Why Karolinska Development AB (publ)'s (STO:KDEV) CEO Compensation May Be Closely ReviewedKey Insights Karolinska Development to hold its Annual General Meeting on 15th of May CEO Viktor Drvota's total...
Reported Earnings • May 02First quarter 2025 earnings released: kr0.053 loss per share (vs kr0.001 profit in 1Q 2024)First quarter 2025 results: kr0.053 loss per share (down from kr0.001 profit in 1Q 2024). Net loss: kr14.2m (down kr14.4m from profit in 1Q 2024). Revenue is forecast to grow 2.6% p.a. on average during the next 2 years, compared to a 24% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 32% per year, which means it is performing significantly worse than earnings.
お知らせ • Apr 08Karolinska Development AB (publ), Annual General Meeting, May 15, 2025Karolinska Development AB (publ), Annual General Meeting, May 15, 2025, at 15:00 W. Europe Standard Time. Location: at nanna svartz vag 2, 17165 solna, Sweden
Reported Earnings • Mar 24Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: kr0.03 loss per share (down from kr0.02 profit in FY 2023). Net loss: kr8.10m (down 250% from profit in FY 2023). Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 67%. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 26% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Reported Earnings • Feb 17Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2024 results: kr0.03 loss per share (down from kr0.02 profit in FY 2023). Net loss: kr8.10m (down 250% from profit in FY 2023). Revenue missed analyst estimates by 8.1%. Earnings per share (EPS) exceeded analyst estimates by 67%. Revenue is forecast to grow 4.2% p.a. on average during the next 2 years, compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 49% per year but the company’s share price has only fallen by 32% per year, which means it has not declined as severely as earnings.
New Risk • Feb 15New major risk - Revenue and earnings growthEarnings have declined by 37% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 37% per year over the past 5 years. Revenue is less than US$1m (kr1.9m revenue, or US$176k). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr24m net loss in 2 years). Market cap is less than US$100m (kr280.6m market cap, or US$26.2m).
お知らせ • Dec 19Karolinska Development AB Announces Changes to ChairmanKarolinska Development AB announced that its Board of Directors has appointed Ben Toogood as new Chairman until the next General Meeting. Karolinska Development’s Board of Directors has internally appointed its member Ben Toogood as new Chairman, following Professor Hans Wigzell’s resignation from the position at his own request. Ben Toogood has been a member of the Board since 2021 and is beyond the assignment also Head of Global Business Development at Sino Pharmaceuticals Limited, CEO at invoX Pharma Limited and Director at Softhale BV and pHion Therapeutics.
お知らせ • Dec 11Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the BoardKarolinska Development AB announced that the company’s Chairman of the Board, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately initiate a process to appoint a new Chairman. Hans Wigzell has been an instrumental force in Karolinska Development ever since the company was founded. He has served as Chairman of the Board during several periods, most recently since the 2024 Annual General Meeting.
Reported Earnings • Nov 17Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023)Third quarter 2024 results: kr0.04 loss per share (down from kr0.044 profit in 3Q 2023). Net loss: kr10.9m (down 191% from profit in 3Q 2023). Revenue is forecast to grow 1.8% p.a. on average during the next 3 years, compared to a 33% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 36 percentage points per year, which is a significant difference in performance.
お知らせ • Nov 15Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF VaccinesKarolinska Development AB announced that its portfolio company SVF Vaccines has appointed Dr Gaston Picchio as acting CEO. He will assume the position with effect from November 15, 2024, as Dr Richard Bethell has decided to step down as CEO to pursue other professional interests while remaining associated with the company in an advisory role. Dr. Gaston Picchio has over 30 years of experience in clinical virology from his previous roles at the Scripps Research Institute, Johnson & Johnson, and Arbutus Biopharma. While at Johnson & Johnson, Dr. Picchio was involved in the development and approval of antivirals and vaccines for HIV, HCV, and Zika. Most recently, he comes from Arbutus Biopharma, where he led the development of novel therapeutic combinations aimed at curing chronic hepatitis B.
お知らせ • Sep 23An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV).An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024. An undisclosed buyer completed the acquisition of 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV) on September 23, 2024.
New Risk • Sep 01New major risk - Revenue and earnings growthEarnings have declined by 26% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m (kr1.9m revenue, or US$185k). Minor Risk Market cap is less than US$100m (kr357.3m market cap, or US$34.8m).
Reported Earnings • Sep 01Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023)Second quarter 2024 results: kr0.059 loss per share (down from kr0.086 profit in 2Q 2023). Net loss: kr16.0m (down 169% from profit in 2Q 2023). Revenue is forecast to grow 1.5% p.a. on average during the next 3 years, compared to a 40% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 45 percentage points per year, which is a significant difference in performance.
お知らせ • Jun 15+ 4 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025Karolinska Development AB (publ) announced that they will report fiscal year 2024 final results on Mar 21, 2025
分析記事 • May 04We Think That There Are Some Issues For Karolinska Development (STO:KDEV) Beyond Its Promising EarningsKarolinska Development AB (publ)'s ( STO:KDEV ) robust recent earnings didn't do much to move the stock. We think this...
Reported Earnings • Apr 28First quarter 2024 earnings releasedFirst quarter 2024 results: Net income: kr208.0k (up kr28.2m from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 25% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 54% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
お知らせ • Apr 16Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-ElectionKarolinska Development AB (publ) announced that Björn Cochlovius has declined re-election.
Reported Earnings • Mar 25Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Revenue is forecast to stay flat during the next 3 years compared to a 23% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
New Risk • Mar 24New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 45% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 45% per year for the foreseeable future. Revenue is less than US$1m (kr2.0m revenue, or US$191k). Minor Risks Large one-off items impacting financial results. Market cap is less than US$100m (kr428.5m market cap, or US$40.5m).
Recent Insider Transactions • Feb 22Chief Executive Officer recently bought kr81k worth of stockOn the 19th of February, Viktor Drvota bought around 50k shares on-market at roughly kr1.62 per share. This transaction amounted to 31% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. This was Viktor's only on-market trade for the last 12 months.
Reported Earnings • Feb 18Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022)Full year 2023 results: EPS: kr0.02 (up from kr0.34 loss in FY 2022). Net income: kr5.39m (up kr93.5m from FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
お知らせ • Feb 03+ 5 more updatesKarolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024Karolinska Development AB (publ) announced that they will report first half, 2024 results on Aug 30, 2024
Reported Earnings • Nov 19Third quarter 2023 earnings released: EPS: kr0.044 (vs kr0.17 loss in 3Q 2022)Third quarter 2023 results: EPS: kr0.044 (up from kr0.17 loss in 3Q 2022). Net income: kr12.0m (up kr58.6m from 3Q 2022). Revenue is forecast to stay flat during the next 3 years compared to a 28% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 11% per year whereas the company’s share price has fallen by 12% per year.
お知らせ • Nov 09Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million.Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 20,150,000 Price\Range: SEK 2 Transaction Features: Rights Offering
お知らせ • Sep 21Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal SurgeryKarolinska Development AB announced that its portfolio company OssDsign has received clearance from FDA for the use of OssDsign Catalyst in interbody cages in spinal surgery. The FDA clearance creates possibilities in a new indication with major market potential for the company's innovative nanosynthetic bone graft. The clearance from the U.S. Food and Drug Administration (FDA) allows surgeons to use the OssDsign Catalyst on-label in any interbody cage cleared for use with synthetic bone grafts. OssDsign Catalyst is the first synthetic bone graft to be cleared to market for interbody use based on bone graft data alone. The decision by the FDA is based on OssDsign's outstanding bone regeneration results which surpass other synthetic bone grafts in challenging evaluation models.
Reported Earnings • Aug 27Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022)Second quarter 2023 results: EPS: kr0.086 (up from kr0.083 loss in 2Q 2022). Net income: kr23.3m (up kr45.6m from 2Q 2022). Revenue is expected to decline by 2.4% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 28%. Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 16% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Jun 22Chief Legal Officer & Deputy CEO recently bought kr165k worth of stockOn the 20th of June, Johan Dighed bought around 100k shares on-market at roughly kr1.65 per share. This transaction amounted to 30% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr466k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • May 08Chief Legal Officer & Deputy CEO recently bought kr56k worth of stockOn the 4th of May, Johan Dighed bought around 35k shares on-market at roughly kr1.61 per share. This transaction amounted to 12% of their direct individual holding at the time of the trade. In the last 3 months, they made an even bigger purchase worth kr89k. Insiders have collectively bought kr301k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Mar 29Chief Legal Officer & Deputy CEO recently bought kr89k worth of stockOn the 27th of March, Johan Dighed bought around 50k shares on-market at roughly kr1.78 per share. This transaction amounted to 20% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr245k more in shares than they have sold in the last 12 months.
Reported Earnings • Mar 28Full year 2022 earnings: EPS and revenues exceed analyst expectationsFull year 2022 results: kr0.34 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue exceeded analyst estimates by 15%. Earnings per share (EPS) also surpassed analyst estimates by 13%. Revenue is expected to decline by 4.3% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 28%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 53 percentage points per year, which is a significant difference in performance.
Reported Earnings • Feb 19Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021)Full year 2022 results: kr3.43 loss per share (down from kr0.97 profit in FY 2021). Net loss: kr88.1m (down 152% from profit in FY 2021). Revenue is expected to decline by 7.1% p.a. on average during the next 2 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 28%. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
お知らせ • Feb 15Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive DataKarolinska Development AB (publ) announced that its portfolio company Dilafor’s extended clinical phase 2b study with the drug candidate tafoxiparin has resulted in further positive data. The extension of the study met its objective, which was to evaluate if the efficacy of tafoxiparin obtained in the phase 2b trial persists when the drug is administered in additional doses. In a clinical phase 2b study, tafoxiparin showed a significant positive effect on cervical ripening in first-time mothers that were given treatment for a planned start of labor. The completed extension of the phase 2b study included a total of 164 women, and the results show that the cervical ripening effect persists in the study. In addition, a clear dose-response relationship was observed. Up to 30% of all pregnant women are subject to planned start of labor, the current interventions increase the risk of medical complications in both mother and child, leading to high healthcare costs. Karolinska Development's direct ownership in Dilafor amounts to 1% and indirect ownership interest via KDev Investment in Dilafor amounts to 30%.
Recent Insider Transactions • Dec 23Chief Legal Officer & Deputy CEO recently bought kr84k worth of stockOn the 19th of December, Johan Dighed bought around 50k shares on-market at roughly kr1.67 per share. This transaction amounted to 25% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought kr156k more in shares than they have sold in the last 12 months.
Reported Earnings • Nov 19Third quarter 2022 earnings releasedThird quarter 2022 results: Net loss: kr46.6m (loss widened kr45.4m from 3Q 2021). Revenue is expected to decline by 3.0% p.a. on average during the next 3 years, while revenues in the Pharmaceuticals industry in Sweden are expected to grow by 33%.
お知らせ • Nov 19+ 1 more updateKarolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023Karolinska Development AB (publ) announced that they will report first half, 2023 results on Aug 25, 2023
お知らせ • Nov 18Karolinska Development AB (publ), Annual General Meeting, May 16, 2023Karolinska Development AB (publ), Annual General Meeting, May 16, 2023.
Price Target Changed • Nov 16Price target decreased to kr5.40Down from kr6.10, the current price target is provided by 1 analyst. New target price is 160% above last closing price of kr2.08. Stock is down 73% over the past year. The company posted earnings per share of kr0.97 last year.
Board Change • Nov 16Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Aug 20Second quarter 2022 earnings releasedSecond quarter 2022 results: Net loss: kr22.3m (down 110% from profit in 2Q 2021). Over the next year, revenue is expected to shrink by 8.1% compared to a 91% growth forecast for the Pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Aug 19+ 2 more updatesKarolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023Karolinska Development AB (publ) announced that they will report fiscal year 2022 results on Feb 17, 2023
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improved over the past weekAfter last week's 20% share price gain to kr3.04, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 10% over the past three years.
Reported Earnings • May 01First quarter 2022 earnings releasedFirst quarter 2022 results: Net loss: kr29.2m (loss widened 17% from 1Q 2021). Over the next year, revenue is expected to shrink by 6.1% compared to a 103% growth forecast for the industry in Sweden.
Price Target Changed • Apr 27Price target increased to kr7.90Up from kr6.10, the current price target is provided by 1 analyst. New target price is 158% above last closing price of kr3.06. Stock is up 98% over the past year. The company posted earnings per share of kr0.97 last year.
Board Change • Apr 27Less than half of directors are independentThere are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 1 experienced director. No highly experienced directors. 2 independent directors (3 non-independent directors). Director Theresa Tse is the most experienced director on the board, commencing their role in 2017. Independent Director Anna Lefevre Skjoldebrand was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors.
Reported Earnings • Mar 29Full year 2021 earnings released: EPS: kr0.97 (vs kr1.18 loss in FY 2020)Full year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Over the next year, revenue is expected to shrink by 7.8% compared to a 112% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 16% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Mar 07Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to kr2.86, the stock trades at a trailing P/E ratio of 4.5x. Average forward P/E is 20x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 47% over the past three years.
Reported Earnings • Feb 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: kr0.97 (up from kr1.18 loss in FY 2020). Net income: kr170.8m (up kr378.3m from FY 2020). Revenue missed analyst estimates by 100%. Over the next year, revenue is expected to shrink by 7.8% compared to a 73% growth forecast for the pharmaceuticals industry in Sweden. Over the last 3 years on average, earnings per share has fallen by 7% per year but the company’s share price has fallen by 17% per year, which means it is performing significantly worse than earnings.
Valuation Update With 7 Day Price Move • Jan 14Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr5.08, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 19x in the Pharmaceuticals industry in Sweden. Total loss to shareholders of 15% over the past three years.
Valuation Update With 7 Day Price Move • Dec 15Investor sentiment deteriorated over the past weekAfter last week's 16% share price decline to kr5.05, the stock trades at a trailing P/E ratio of 3.2x. Average forward P/E is 20x in the Pharmaceuticals industry in Sweden. Total loss to shareholders of 21% over the past three years.
Reported Earnings • Nov 19Third quarter 2021 earnings releasedThird quarter 2021 results: Net loss: kr1.20m (loss narrowed 99% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has remained flat, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Nov 10Investor sentiment improved over the past weekAfter last week's 22% share price gain to kr4.68, the stock trades at a forward P/E ratio of 12x. Average forward P/E is 22x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 34% over the past three years.
Valuation Update With 7 Day Price Move • Oct 26Investor sentiment improved over the past weekAfter last week's 17% share price gain to kr4.22, the stock trades at a forward P/E ratio of 10x. Average forward P/E is 24x in the Pharmaceuticals industry in Europe. Total loss to shareholders of 42% over the past three years.
Valuation Update With 7 Day Price Move • Sep 10Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to kr4.05, the stock trades at a trailing P/E ratio of 6.6x. Average trailing P/E is 113x in the Pharmaceuticals industry in Sweden. Total loss to shareholders of 53% over the past three years.
Reported Earnings • Aug 21Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020)Second quarter 2021 results: Net income: kr216.4m (up kr214.3m from 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 50% per year but the company’s share price has only fallen by 17% per year, which means it has not declined as severely as earnings.
分析記事 • Aug 19Is Karolinska Development (STO:KDEV) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • May 01First quarter 2021 earnings releasedFirst quarter 2021 results: Net loss: kr24.9m (loss narrowed 80% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 38% per year, which means it has not declined as severely as earnings.
分析記事 • Apr 27Karolinska Development AB (publ)'s (STO:KDEV) CEO Might Not Expect Shareholders To Be So Generous This YearKarolinska Development AB (publ) ( STO:KDEV ) has not performed well recently and CEO Viktor Drvota will probably need...
Reported Earnings • Mar 30Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 33% per year, which means it has not declined as severely as earnings.
Executive Departure • Mar 10CFO & Deputy CEO Fredrik Jarrsten has left the companyOn the 7th of March, Fredrik Jarrsten, was replaced as CEO by Viktor Drvota. As of December 2020, Fredrik personally held only 120.00k shares (kr216k worth at the time). A total of 5 executives have left over the last 12 months.
Is New 90 Day High Low • Feb 25New 90-day low: kr1.59The company is down 31% from its price of kr2.31 on 27 November 2020. The Swedish market is up 8.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 9.0% over the same period.
Reported Earnings • Feb 13Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019)Full year 2020 results: Net loss: kr207.5m (down 169% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 52% per year but the company’s share price has only fallen by 35% per year, which means it has not declined as severely as earnings.